Literature DB >> 3899969

Review of pharmacological data on benzydamine.

V Cioli, C Corradino, P Scorza Barcellona.   

Abstract

Pharmacological results are reviewed supporting the use of benzydamine in so-called "primary inflammations" rather than in rheumatic diseases. In experimental studies, benzydamine shares with aspirin-like drugs their activity in acute inflammatory responses but not in Freund's adjuvant arthritis. The efficacy of benzydamine is mainly manifested against phenomena such as pain and oedema which depend on local mechanisms in the inflammatory focus. Other manifestations such as hyperthermia which are indicative of systemic functional involvement, are poorly affected by the drug. Benzydamine also lacks some of the typical side-effects of aspirin-like drugs which are thought to reflect their generalized activity. Finally topical application increases the analgesic and antiinflammatory activities of benzydamine much more than those of other antiinflammatory drugs. The data reported demonstrate that benzydamine specifically acts on the local mechanisms of inflammation. In order to explain this feature the chemical, pharmacokinetic and biochemical properties of benzydamine are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3899969

Source DB:  PubMed          Journal:  Int J Tissue React        ISSN: 0250-0868


  5 in total

1.  Animal models for the study of atypical anti-inflammatory agents.

Authors:  B Silvestrini
Journal:  Agents Actions       Date:  1986-01

2.  Benzydamine inhibits monocyte migration and MAPK activation induced by chemotactic agonists.

Authors:  Elena Riboldi; Giada Frascaroli; Pietro Transidico; Walter Luini; Sergio Bernasconi; Francesca Mancini; Angelo Guglielmotti; Claudio Milanese; Mario Pinza; Silvano Sozzani; Alberto Mantovani
Journal:  Br J Pharmacol       Date:  2003-08-18       Impact factor: 8.739

3.  Pharmacokinetics of benzydamine in dairy cows following intravenous or intramuscular administration.

Authors:  P Anfossi; J Malvisi; N Catraro; M Bolognini; L Tomasi; G L Stracciari
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

4.  Pharmacology of benzydamine.

Authors:  P A Quane; G G Graham; J B Ziegler
Journal:  Inflammopharmacology       Date:  1998       Impact factor: 4.473

5.  Benzydamine inhibits osteoclast differentiation and bone resorption via down-regulation of interleukin-1 β expression.

Authors:  Han Saem Son; Jiae Lee; Hye In Lee; Narae Kim; You-Jin Jo; Gong-Rak Lee; Seong-Eun Hong; Minjeong Kwon; Nam Young Kim; Hyun Jin Kim; Jin Ha Park; Soo Young Lee; Woojin Jeong
Journal:  Acta Pharm Sin B       Date:  2019-11-08       Impact factor: 11.413

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.